"Future Search Trials - Austin partners with leading therapeutic and pharmaceutical companies in the pursuit of improved medical treatment for conditions and diseases such as chronic pain, osteoarthritis, insomnia, and pain after shingles. Participants of clinical trials at Future Search Trials-Austin benefit from our studies by: - Helping improve medical treatments for yourself and others - Providing invaluable information to organizations spear-heading medical treatments - Getting compensated for your time and participation - Receiving access to FDA-approved depression treatment you might not be able to find in a traditional medical setting"

During the past decade, FutureSearch Trials of Neurology conducted 99 clinical trials. In the 10-year time frame, 99 clinical trials started and 113 clinical trials were completed, i.e. on average, 114.1% percent of trials that started reached the finish line to date. In the past 5 years, 46 clinical trials started and 48 clinical trials were completed. i.e. 104.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "FutureSearch Trials of Neurology" #1 sponsor was "Pfizer" with 28 trials, followed by "Shire" with 24 trials sponsored, "Sunovion" with 20 trials sponsored, "Eli Lilly and Company" with 15 trials sponsored and "Jazz Pharmaceuticals" with 15 trials sponsored. Other sponsors include 131 different institutions and companies that sponsored additional 71 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "FutureSearch Trials of Neurology" #1 collaborator was "BrainCells Inc." with 2 trials as a collaborator, "CoLucid Pharmaceuticals" with 2 trials as a collaborator, "Purdue Pharma LP" with 2 trials as a collaborator, "Camurus AB" with 1 trials as a collaborator and "GlaxoSmithKline" with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "FutureSearch Trials of Neurology" are "Major Depressive Disorder" (30 trials), "Schizophrenia" (22 trials), "Migraine" (15 trials), "ADHD" (11 trials) and "Low Back Pain" (9 trials). Many other conditions were trialed in "FutureSearch Trials of Neurology" in a lesser frequency.

Most popular intervention types in "FutureSearch Trials of Neurology" are "Drug" (222 trials), "Other" (14 trials), "Device" (7 trials), "Biological" (4 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (120 trials), "placebo" (13 trials), "Lurasidone" (8 trials), "Rimegepant" (6 trials) and "Galcanezumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "FutureSearch Trials of Neurology" are 230 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "FutureSearch Trials of Neurology". undefined are not yet recruiting, 14 are recruiting, 7 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 189 completed trials in FutureSearch Trials of Neurology, undefined suspended trials, and 17 terminated clinical trials to date.

Out of the total trials that were conducted in FutureSearch Trials of Neurology, 1 "Phase 1" clinical trials were conducted, 74 "Phase 2" clinical trials and 135 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 24 trials, and there were also 7 trials that are defined as “Not Applicable".